AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF
Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA AC01, a novel, selective oral ghrelin receptor (GHSR1a) agonist, is currently in Phase IIa (GOAL-HF1) and the advice will enable the planned […]